NEVANAC: new ophthalmic NSAID coming soon..

In September, Alcon plans to introduce Nevanac (nepafenac ophthalmic suspension 0.1%) for the management of pain and inflammation associated with cataract surgery.
Nepafenac is a nonsteroidal anti-inflammatory and analgesic prodrug. After ocular administration, it penetrates the cornea and is hydrolyzed to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibit the action of cyclooxygenase, an enzyme required for prostaglandin synthesis.
Nevanac suspension shuld be shaken well before use. The recommended dosage is one drop instilled into the affected eye(s) three times daily, beginning one day prior to cataract surgery. The drops should be continued on the day of surgery and for the first two weeks after surgery.
The most common adverse effects are eye disorders (e.g., eyelid crusting, eye pain, blurred vision, foreign body sensation, eye pruritus,tearing) and headache.
Systemic exposrue is very low after ocular administration. However, there is the protential for cross sensitivity between nepafenac and other NSAIDs, including acetylsalsalicylic acid (Aspirin).